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Abstract
In the search for new drug targets, we evaluated the biotin synthetic pathway of Mycobacterium tuberculosis (Mtb) and
constructed an Mtb mutant lacking the biotin biosynthetic enzyme 7,8-diaminopelargonic acid synthase, BioA. In biotin-free
synthetic media, DbioA did not produce wild-type levels of biotinylated proteins, and therefore did not grow and lost
viability. DbioA was also unable to establish infection in mice. Conditionally-regulated knockdown strains of Mtb similarly
exhibited impaired bacterial growth and viability in vitro and in mice, irrespective of the timing of transcriptional silencing.
Biochemical studies further showed that BioA activity has to be reduced by approximately 99% to prevent growth. These
studies thus establish that de novo biotin synthesis is essential for Mtb to establish and maintain a chronic infection in a
murine model of TB. Moreover, these studies provide an experimental strategy to systematically rank the in vivo value of
potential drug targets in Mtb and other pathogens.
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Introduction
Mtb causes approximately 8 million new cases of active
tuberculosis (TB) and 2 million deaths each year [1]. Efforts to
combat the TB pandemic have been hampered by the emergence
of drug resistant strains of Mtb [2]. TB drug development thus
represents a major area of unmet medical need. Mtb is shielded
from the environment by a complex envelope that consists of an
inner membrane, a periplasmic space, an outer membrane and a
loosely attached capsule [3–5]. Isoniazid (INH), ethionamide
(ETH) and ethambutol (EMB) constitute three anti-tuberculosis
drugs that specifically inhibit synthesis of this envelope and
validate cell envelope biosynthesis as a target pathway in Mtb.
Biotinisanessentialcofactorrequiredforsynthesisofthefattyacid
component of Mtb’s cell envelope [6–10] and is synthesized from
pimeloyl-CoA via a pathway consisting of four enzymes, BioF, BioA,
BioD and BioB(Figure1A) [11].Bioactivity of biotinfurther requires
covalent attachment to an enzyme, via a biotin ligase [12]. While the
source of pimeloyl-CoA in Mtb is unknown [13], mammalian cells
lack the enzymes to synthesize biotin de novo and must acquire it from
external sources. Based on this presumed essentiality and intrinsic
bacterial specificity, we sought to validate biotin biosynthesis as a
potential target for the development of new antibiotics.
That efficient inhibition of biotin synthesis by a small molecule
can be achieved was demonstrated by the ability of amiclenomycin,
a natural product inhibitor of BioA isolated from Streptomyces
lavendulae [14], to prevent in vitro growth of Mtb in media lacking
exogenous biotin [15]. Treatment of mice with amiclenomycin had
no impact on infection with Mtb, which was interpreted as evidence
that Mtb does not depend on biotin synthesis during infection and is
instead able to scavenge this cofactor from the host [16]. However,
the lack of pharmacokinetic data showing that the organism was, in
fact, exposed to the drug in these experiments temper this
conclusion. In contrast, genome wide mutagenesis studies identified
transposon insertion mutants of biotin synthesis genes as among the
most highly attenuated mutants of Mtb observed in mice [17],
suggesting that Mtb cannot access exogenous biotin in mice. Here,
we constructed genetically defined Mtb bioA mutants to determine
the consequences of inhibiting biotin synthesis on growth and
survival of Mtb in vitro and during acute and chronic mouse
infections.
Results
BioA is required for protein biotinylation, and therefore
the growth and survival of Mtb without exogenous biotin
The Mtb bioA gene is located upstream of bioF1, bioD, and a gene
of unknown function, rv1571 (Figure 1B). The start codons of bioF,
bioD, and rv1571 are each positioned directly upstream of the
stop codons of their respective upstream genes. This overlapping
PLoS Pathogens | www.plospathogens.org 1 September 2011 | Volume 7 | Issue 9 | e1002264genetic organization suggests that both transcription and transla-
tion of bioA, bioF1, bioD and rv1571 mRNAs are coupled. We
therefore generated a knockout cassette consisting of a hygromycin
resistance gene flanked by 451 bp of rv1567c and its putative
promoter on one end, and the putative bioA promoter followed by
the first 723 bp of bioF1 on the other (Figure 1B). Integration of
this cassette into the genome of Mtb H37Rv deleted bioA and
placed the DNA fragment predicted to contain the promoter and
the translational initiation site of bioA upstream of bioF1. Creation
of this deletion mutant, DbioA, was confirmed by Southern Blot
(Figure 1C).
As expected, DbioA did not grow in liquid media without added
biotin but could be rescued with exogenous biotin or des-thiobiotin
(DTB), the substrate of the biotin synthase, BioB (Figure 2A). No
rescue occurred with 7-keto-8-aminopelargonic acid (KAPA), the
substrate of BioA. DbioA growth was dependent on the
concentration of biotin in the media (Figure 2B); with little to no
growth with exogenous biotin concentrations below 25 nM and
wild-type (wt) levels of growth above 250 nM biotin. Anti-biotin
immunoblotting similarly revealed a selective loss of immunore-
activity corresponding to a single protein in DbioA, but not wt Mtb,
following 6 days of biotin starvation (Figure 2C). The electropho-
retic mobility and anti-biotin immunoreactivity of this protein
suggests that it corresponds to AccA3, one of three proteins
predicted to be biotinylated in Mtb [6,18].
We also assessed the impact of biotin starvation on DbioA
viability by enumerating the colony forming units (CFUs)
recovered after incubation for various time in Sauton’s medium
without biotin. DbioA CFUs decreased from 10
7 CFUs per ml to
less than 10
2 CFUs per ml over a period of 50 days (Figure 2D). In
the same medium, the CFUs of wt Mtb increased during the first
two weeks and remained stable thereafter. CFUs recovered for wt
and DbioA from biotin-containing Sauton’s medium were almost
identical. These experiments thus demonstrate that selective
deletion of bioA caused a specific defect in Mtb’s biotin biosynthesis
pathway as reported by biotin-dependent changes in protein
biotinylation, growth and survival of DbioA but not wt Mtb.
BioA is required for Mtb to establish acute infection in
mice
Mtb mutants harboring transposon insertions in biotin synthesis
genes were among the most strongly attenuated during infection of
mouse spleens by pooled mutants [17]. We sought to extend these
studies by measuring the extent to which Mtb depends on de novo
biotin biosynthesis for growth in mouse lungs during acute, single-
strain infection and for persistence in the chronic phase of
infection. Whereas DbioA could address the first question, a mutant
that enabled conditional silencing of bioA during the chronic phase
of infection was required to answer the second. We therefore
constructed a tetracycline repressor (TetR)-regulated mutant in
which transcription of bioA can be induced with either anhydrote-
tracycline (atc) or doxycycline (doxy), but was inhibited in their
absence. To achieve this, we cloned the bioA gene downstream of
the TetR-controlled promoter Pmyc1tetO [19] into a plasmid, which
also contained a tetR whose codon usage was adapted to improve
expression in mycobacteria [20]. Integration of the resulting
plasmid, pGMCK-T2M1-bioA, into the attachment site of the
phage L5 (attL5) yielded Mtb bioA TetON-1.
Growth of bioA TetON-1 in biotin-free medium was indistin-
guishable from that of wt Mtb in the presence of atc, but reduced,
though not abolished as observed for DbioA, in its absence
(Figure 3A). Growth of wt, DbioA, and bioA TetON-1 in biotin-
containing media, by contrast, was indistinguishable. Following
aerosol infection, DbioA did not grow in mouse lungs. The bioA
TetON-1 mutant grew slightly more slowly in mice not receiving
doxy than in mice that were fed doxy but it reached a similar final
bacterial load in lungs with and without doxy (Figure 3B). In vitro
growth analyses confirmed that bioA TetON-1 bacteria recovered
from mouse lungs at day 56 post-infection were still TetR
regulated and did not represent suppressor mutants (not shown).
In contrast to the muted phenotype of bioA TetON-1, DbioA was
strongly attenuated and no or few CFUs were recovered 56 days
post infections (Figure 3B). BioA is thus required for Mtb to
establish an acute infection in mouse lungs.
Construction of tightly controlled Mtb bioA-TetON
mutants
To compare BioA protein levels of bioA TetON-1 with those of
wt and DbioA, we grew them (with biotin) in the presence and
absence of atc and analyzed total protein extracts with BioA-
specific polyclonal antiserum. As expected, no BioA was detected
in DbioA and BioA expression was not changed by atc in wt Mtb
(Figure 4A). In bioA TetON-1 extracts prepared from atc-
containing cultures BioA protein exceeded the wt levels, but BioA
protein was not detected in extracts of cultures grown without atc.
Because bioA TetON-1 grew, albeit more slowly, in the absence of
both atc and biotin (Figure 3A), these results suggested that the
amount of BioA expressed by wt is actually significantly higher
than required for growth in biotin-free media.
The immunoblots also indicated that induction of BioA by atc
in bioA TetON-1 was stronger than necessary to achieve full
complementation. Seven nucleotides upstream of the bioA start
codon, the bioA mRNA of bioA TetON-1 contains a hexamer that
is perfectly complementary to the region of Mtb’s 16S rRNA
thought to bind mRNAs during the initiation of translation. We
sought to improve regulation of BioA expression by mutating this
putative ribosome binding site (Shine-Dalgarno site, SD) and
constructed three mutants, bioA TetON-2/-3/-4, in which
individual nucleotides were mutated as shown in Figure 4B. In
the fifth mutant, bioA TetON-5, all nucleotides of the SD were
changed to decrease binding of the bioA TetON-5 mRNA to the
Author Summary
We evaluated the biotin synthetic pathway of Mycobacte-
rium tuberculosis (Mtb) as a new drug target by first
generating an Mtb deletion mutant, DbioA, in which the
biotin biosynthetic enzyme 7,8-diaminopelargonic acid
synthase (BioA) has been inactivated. This mutant grew in
the presence of biotin or des-thiobiotin, but not with an
intermediate of the biotin biosynthesis pathway that
requires BioA to be converted into biotin. Without
exogenous biotin or des-thiobiotin, DbioA, was unable to
produce biotinylated proteins, which are required for the
biosynthesis of fatty acids, and thus died in biotin-free
media. Using a regulatable promoter and different
ribosome binding sequences we next constructed tightly
controlled TetON mutants, in which expression of BioA
could be induced with tetracyclines, but was inhibited in
their absence. Characterization of these mutants during
infections demonstrated that de novo biotin synthesis is
not only required to establish infections but also to
maintain bacterial persistence. Inhibition of BioA or other
enzymes of the biotin biosynthesis pathways could thus
be used to kill Mtb during both acute and chronic
infections. Biochemical and immunological analyses of
different Mtb mutants indicate that drugs targeting BioA
would have to inactive approximately 99% of its activity to
be effective.
Conditional Mtb bioA Knockdown Mutants
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BioA than bioA TetON-1 and the lowest amount of BioA was
detected in extracts of bioA TetON-5 (Figure 4A). The experiments
shown in Figure 4A did not allow us to measure BioA expression
in the different TetON mutants without atc, but we expected that
mutations in the SD also decreased the amount of BioA expressed
by each mutant in the absence of atc and tested this by measuring
growth without biotin.
In contrast to bioA TetON-1 (Figure 3A), bioA-TetON-2/-3/-4/
-5 all failed to grow in biotin-free media lacking atc. With atc,
growth of the new mutants was indistinguishable from growth of
wt and from growth with biotin (Figure 5A and Figure S1).
Moreover, growth of the mutants was strictly atc-dose dependent
(Figure S2 and not shown). Next, we infected mice and monitored
growth of DbioA and all five bioA TetON mutants without doxy
(Figure 5B). Similar CFU counts were recovered from mouse lungs
for all mutants 1 day after the aerosol infection. 21 days post
infection, the CFUs recovered from the mice infected with bioA
TetON-1 had increased from 161 (611) to 136,800 (631,704)
whereas the CFUs of DbioA and bioA TetON-2/-3/-4/-5 were
close to or below the limit of detection.
Together, these experiments demonstrated that (i) BioA levels in
wt Mtb are significantly above those required for growth without
exogenous biotin, (ii) efficient regulation of BioA expression by
TetR and Pmyc1tetO required mutation of the ribosome binding
sequence, and (iii) conditionally silenced Mtb bioA strains TetON-
2/3/4/5 could not replicate in mouse lungs in the absence of
doxy.
BioA is essential for persistence of Mtb during chronic
infections
Expression of BioA was lowest in bioA TetON-5 (Figure 4)
suggesting that this mutant might also allow most efficient
silencing of BioA without atc. We therefore selected it to determine
the extent to which Mtb requires BioA to persist during the chronic
phase of infection in a murine model of TB and silenced bioA
transcription on days 1, 10, 28 or 56 post infection. In accordance
with the infection described above (Figure 5B), bioA TetON-5
failed to grow in mice that never received doxy (Figure 6), with no
more than 4 CFUs isolated from lungs 56 days post infection and
none recovered after 112 days. In the absence of doxy, bioA
TetON-5 thus reproduced the phenotype of DbioA (Figure 3B).
Figure 1. Biotin synthesis pathway and construction of Mtb DbioA. (A) Shown are the reactions catalyzed by KAPA synthase (BioF), DAPA
synthase (BioA), DTB synthase (BioD) and biotin synthase (BioB), which convert pimeloyl-CoA to biotin, and biotin ligase, which attaches the cofactor
to biotin-dependent enzymes. (B) The upper panel displays the genetic organization of the bioA region in wt Mtb; the lower panel displays that of
DbioA. Gray boxes represent open reading frames of the genes specified above or below, the striped boxes mark the putative bioA promoter, and the
black boxes represent hygR. The localization of recognition sites for the restriction endonuclease DraIII are labeled ‘‘D’’. (C) Southern blot of DraIII-
digested genomic DNA from wt Mtb and DbioA. The expected sizes for the DraIII fragments hybridizing to the bioF1-derived probe that was used in
this blot are 3068 bp for wt and 4021 bp for DbioA.
doi:10.1371/journal.ppat.1002264.g001
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lungs increased during approximately four weeks, were almost
constant in lungs and spleens thereafter, and were very similar to
CFUs of wt Mtb H37Rv. Deprivation of biotin after the first 10
days resulted in growth impairment of bioA TetON-5 in lungs and
spleens and perhaps more importantly caused a subsequent
decline of CFUs to less than 0.02% of the day 28 CFUs from
lungs by 224 days post infection. By that time no CFUs could be
recovered from the spleens of these bioA TetON-5 infected mice.
When biotin deprivation was initiated 28 days post-infection, the
CFUs in lungs decreased by more than 99% at day 168. Due to a
technical problem we did not obtain data for this group of mice
224 days post infection (or the wt control). However, silencing bioA
even later in the chronic phase of the infection, at day 56, resulted
in a ,96% reduction in bacterial numbers recovered from lungs at
day 224. Histological analyses demonstrated that silencing of BioA
expression 10 days post infection prevented the severe pathology
caused by bioA TetON-5 with doxy and that inactivation of BioA
Figure 2. In vitro characterization of Mtb DbioA. (A) Growth of DbioA in Sauton’s medium (left) or Sauton’s medium supplemented with KAPA,
DTB or biotin. Data are from individual cultures and representative of at least two independent experiments. (B)Growth of DbioA in Sauton’s medium
with varying concentrations of biotin. Data are from individual cultures and representative of at least two independent experiments. (C) Immunoblots
performed with both an anti-biotin antiserum and rabbit serum recognizing Mtb’s dihydrolipoamide acyltransferase (DlaT). The lower panel shows
the signal from the anti-biotin antibody; the upper panel shows the DlaT signal, which served as the loading control. Protein extracts were prepared
after the indicated days of cultivation in biotin-free Sauton’s medium. Data are from individual cultures and representative of at least two
independent experiments. (D) Survival of wt and DbioA in Sauton’s media with and without biotin. Data are averages from triplicate cultures and
representative of at least two independent experiments. Error bars indicate standard deviations.
doi:10.1371/journal.ppat.1002264.g002
Conditional Mtb bioA Knockdown Mutants
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In summary, these experiments demonstrated that bioA expression
is required for Mtb to both establish and maintain infection in a
murine model of TB.
Quantitative analyses of the BioA levels and activities of
different mutants
Our final goal in this study was to determine the minimal level
of BioA expression required for in vitro growth and survival of Mtb
in mice. To do so, we first analyzed immunoblots that contained
serial dilutions of total protein extract for all TetON mutants. The
intensity of the BioA band in these blots was measured using an
Infrared Imaging System, normalized to the total protein amount
loaded, and compared to wt protein extracts. Two representative
immunoblots of this kind are shown in Figure 7 and the relative
BioA levels measured by this approach are shown in Table 1.
We next developed a coupled assay to measure BioA activities in
cell lysates using BioD catalyzed formation of DTB. In this assay,
saturating concentrations of substrates and cofactors were added
to cell lysates along with recombinant BioD to catalyze conversion
Figure 3. Growth of wt Mtb, DbioA, and bioA TetON-1 in liquid media and mice. (A) Growth of wt, DbioA, and bioA TetON-1 in Sauton’s
media, Sauton’s media with atc or Sauton’s media with biotin. Squares, circles, and triangles represent data for wt, DbioA, and bioA TetON-1,
respectively. Data are from individual cultures and representative of several independent experiments. (B)Growth of DbioA and bioA TetON-1 in
mouse lungs. Circles represent data for DbioA, triangles represent data for bioA TetON-1. Doxy was either given from day 1 of the infection or not at
all. Data displayed by open symbols and dotted lines are from doxy-free mice, closed symbols represent data from doxy-fed mice. Data are averages
from four mice per group; error bars represent the standard error of the mean.
doi:10.1371/journal.ppat.1002264.g003
Figure 4. BioA protein levels of wt Mtb, DbioA, and bioA TetON mutants. (A) Immunoblots performed with anti-BioA antiserum using total
protein extracts prepared from cultures grown with biotin. The plus and minus signs indicate presence or absence of atc in the culture medium. The
first lane on the left contained purified BioA. (B) The putative Shine-Dalgarno sequence of bioA TetON-1 is shown in bold. The mutations that were
introduced and distinguish the different TetON mutants are shown below. ‘‘ATG’’ indicates the start of the bioA.
doi:10.1371/journal.ppat.1002264.g004
Conditional Mtb bioA Knockdown Mutants
PLoS Pathogens | www.plospathogens.org 5 September 2011 | Volume 7 | Issue 9 | e1002264of DAPA into DTB. DTB was then purified from the reaction
mixture using streptavidin agarose resin and eluted into buffer by
thermal treatment of the resin (Figure S4). DTB was subsequently
detected by displacement of the fluorescent DTB probe N
1-[3-
[2-(2-{3-[(Fluorescein-5-yl)carbonyl]aminopropoxy}ethoxy)ethoxy]
propyl}dethiobiotinamide (Fl-DTB) from streptavidin resulting in
an increase in the fluorescent signal. This assay proved to be
extremely sensitive and enabled detection of as little as 30
femtomoles of BioA in the cell lysates. The amount of DTB
produced was directly proportional to the concentration of BioA
(Figure S5). For each assay a standard curve was generated by
adding known amounts of DTB to DbioA lysates (Figure S6). The
relative BioA activity measured by this approach is also shown in
Table 1.
BioA expression levels estimated by immunoblotting were
somewhat lower than those obtained by the coupled enzyme
assay but generally in good agreement with the results of this BioA
activity assay. Both assays demonstrated that regulation of
expression of bioA in bioA TetON-1 was efficient and without atc
the BioA activity of this mutant was reduced by ,96% compared
to wt Mtb (Table 1). For bioA TetON-2/3/4/5 BioA protein levels
and activities were reduced by at least 99%.
Discussion
Here, we report an Mtb mutant, DbioA, in which the entire open
reading frame encoding DAPA synthase was deleted, to evaluate
the in vitro and in vivo characteristics of Mtb’s BioA as a potential
drug target. Deletion of bioA was confirmed genotypically
(Figure 1C) and phenotypically in experiments showing that DbioA
expressed no BioA protein (Figure 4A), had no BioA activity
(Table 1), and produced decreasing amounts of biotinylated
protein after transfer into biotin-free media (Figure 2C). In biotin-
free medium, DbioA lost viability (Figure 2D) with kinetics similar
to those observed for an Mtb bioF mutant [11]. The in vitro growth
defect of DbioA could be complemented with biotin at concentra-
tions as low as 50 nM (Figure 2B), which is at least 25-times higher
than the biotin concentration in human serum [21,22]. Growth of
DbioA was also rescued with DTB, but not using KAPA as a
substrate since conversion of KAPA to biotin is BioA-dependent
(Figures 1A and 2A). Following aerosol infection, DbioA failed to
replicate in mice and was cleared from the lungs of several mice
during the first 8 weeks of the infection (Figures 3B and 5B).
Survival of an M. smegmatis mutant, which contains a transposon
insertion in bioA (referred to as 272A), was impaired during
stationary phase even in the presence of exogenous biotin [23].
That we did not observe such a defect for Mtb DbioA (Figure 2D)
suggests that M. smegmatis and Mtb differ with respect to the
conditions in which they are able to utilize exogenous biotin.
However, what exactly caused the survival defect of M. smegmatis
272A is not entirely clear because this mutant required several
vitamins to grow and it is unknown if a wt copy of bioA would
complement its stationary phase survival defect [23]. What is clear,
however, is that the growth and survival defects that Mtb DbioA
displayed in vitro and during infections can be complemented by
expression of an intact copy of bioA (Figures 3, 5A, 6, S1, S2, and
S3). Our experiments thus demonstrate that Mtb cannot acquire
biotin from the host and requires de novo biotin biosynthesis to both
establish and maintain a chronic infection in a murine model of
TB. This dependence on de novo biotin biosynthesis is likely
conserved in other mycobacterial pathogens, as a biotin auxotroph
of M. marinum was also attenuated [13].
To determine Mtb’s dependency on biotin synthesis over the
course of infection, we constructed TetON mutants, in which
transcription of bioA was induced with atc or doxy and repressed
in the absence of both tetracycline derivatives. This allowed us to
deprive Mtb of its ability to synthesize biotin after it had grown
to more than 1,000 CFUs in both lungs and spleens or had
already established a chronic infection. Irrespective of the stage
of the infection at which shutdown of bioA was initiated, it always
had a severe impact on growth and survival of Mtb (Figure 6). In
mice that received doxycycline from day 1 to day 10, CFUs
increased for approximately 18 more days. That the switch from
doxy-containing to doxy-free food did not result in a more
immediate impact is likely because BioA, biotin, and the
biotinylated enzymes that were synthesized prior to removal of
doxy have to be depleted or inactivated before survival of Mtb is
affected. Beginning on day 28 post infection, CFUs in the lungs
Figure 5. Growth of Mtb bioA TetON-5 in biotin free liquid media and of all mutants in mice without doxy. (A) Growth of wt and bioA
TetON-5 in biotin-free Sauton’s medium with and without atc. Squares represent data for wt, triangles represent data for bioA TetON-5. Open
symbols indicate data from medium without atc, closed symbols represent data from medium containing atc. Data are from individual cultures and
representative of at least two independent experiments. (B) Growth of wt, DbioA and the different bioA TetON mutants in mouse lungs. Closed
symbols represent CFUs from day 1 post infection, open symbols represent data from day 21. The dotted line indicates the limit of detection (which
was lower for wt and DbioA than for the TetON mutants due to the different amounts of lung homogenates that were plated). Each symbol
represents CFUs obtained from one mouse.
doi:10.1371/journal.ppat.1002264.g005
Conditional Mtb bioA Knockdown Mutants
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caused most mice to have less than 4 CFUs per lungs 224 days
post infection. If silencing was initiated at 28 or 56 days post
infection lung CFUs decreased with rates of 12% (61%) and
10% (61%) per week, respectively, at later time points. Silencing
of bioA also had a drastic impact on survival of Mtb in mouse
spleens (Figure 6B) and histological studies demonstrated that
silencing bioA during chronic infections decreased lung pathol-
ogy at later timer points (Figure S3). These data do not prove
that silencing bioA at the later time points can actually sterilize a
chronic infection in the lungs. However, once the CFUs started
t od e c r e a s et h e yc o n t i n u e dt od os ow i t hs i m i l a rk i n e t i c s
irrespectively of the time point at which silencing was initiated,
which suggests that sterilization would have occurred eventually.
Taken together, this demonstrates that Mtb relies on biotin
synthesis for growth and survival throughout the course of
mouse infections. It furthermore indicates that the reported
inactivity of amiclenomycin in Mtb infected mice [16], may have
been due to poor pharmacokinetic behavior of this compound, a
conjecture supported by our observation that amiclenomycin
spontaneously decomposes through aromatization (Orisadipe,
A . ,B o s h o f f ,H .I . ,B a r r y ,C .E . ,u n p u b l i s h e dr e s u l t s ) .
We previously pointed out that genetic drug target validation
studies often fall short of assessing the vulnerability of a target to
partial inhibition [24]. This is relevant because chemical
inactivation of a target during an infection is likely incomplete
and enzymes that need to be inactivated by, for example, 80%
will, on average, make better targets than those that need to be
inactivated by 99% before a pathogen stops replicating. We
employed two approaches, protein level and protein activity
measurements, to determine the extent to which BioA needs to be
inactivated before Mtb stops growing. In general, these two
approaches gave similar results but minor discrepancies were
apparent for mutants that expressed low levels of BioA in the
presence of atc. This was likely due to very low signal intensities in
the respective immunoblots. Both analysis methods indicated that
inactivation of BioA has to reach more than 90% before growth of
Mtb is severely affected in vitro or during infections. This is because
Mtb bioA TetON-1 still grew without atc and without biotin in vitro
and also grew without doxy in mice even though its BioA protein
level and activity were reduced by more than 90% without atc/
doxy. Mutants in which the expression and activity of BioA was
reduced by at least 99% showed strong growth and survival defects
in vitro and during infection.
It is impossible to compare vulnerability of BioA to incomplete
inhibition to that of other potential Mtb drug targets because BioA is
the first Mtb protein for which vulnerability has been measured. But
studies in which vulnerability of different essential enzymes to
incomplete depletion was measured have recently been published
for M. smegmatis [25,26]. These studies suggest that BioA might not
be a highly vulnerable target because reducing expression of the
RNA polymerase subunit B, RpoB, by as little as 80% was sufficient
to prevent growth in M. smegmatis [26] and similar levels of
inactivation might suffice to stop replication of Mtb as well. It thus
seems prudent to determine if other enzymes in the biotin synthesis
pathway might be more susceptible to partial inactivation than
BioA. However, the reported activity of amiclenomycin against
whole Mtb cells suggests that sufficiently potent inhibitors of BioA
can be obtained and the structure of amiclenomycin provides a
starting point for their design. We expect the mutants we described
here to help with the development of such amiclenomycin
derivatives and the identification, evaluation and development of
other inhibitors of Mtb’s biotin metabolism, because they should be
more susceptible than wt to such inhibitors.
Amiclenomycin is known to covalently inactivate BioA in the
process of aromatization [27] thus leading to an unusual situation
analogous to 100% enzyme inhibition. A recently appreciated
variable in determining target vulnerability is the ability to
identify inhibitors with long residence times such as those that
form covalent linkages or that induce conformational changes
upon binding their targets. In TB residence time may be
correlated with in vivo effect [28]. Such factors would seem likely
to be more important with relatively invulnerable targets such as
Figure 6. Growth and survival of Mtb bioA TetON-5 in mouse
lungs and spleens. (A) Growth and persistence in lungs. Squares
represent data for wt, circles represent data for bioA TetON-5. Mtb bioA
TetON-5 was analyzed in mice that did not receive doxy (red circles),
received doxy from day 1 to day 10 (blue circles), from day 1 to day 28
(purple circles), from day 1 to 56 (brown circles) or received doxy
throughout the infection (black circles). Data are averages from at least
four mice and two independent infections; error bars represent the
standard error of the mean. The limit of detection was 4 CFUs per lung.
Dotted lines end in data points for which most of the lungs contained 4
or fewer CFUs. The red asterisk indicates that no CFUs were recovered
from any of the no-doxy mice 112 days post infection. (B) Persistence in
spleens. The blue asterisk indicates that on day 224 no CFUs were
recovered from any of the mice that received doxy up to day 10.
Otherwise as described for (A).
doi:10.1371/journal.ppat.1002264.g006
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inhibition required for an effect on growth is, of course, only one
factor important in determining the overall target vulnerability.
Nonetheless such information offers an important new way to
prioritize potential targets within a biochemical pathway and may
explain some of the failure in translating highly potent inhibitors
of essential enzymes into compound series with high cellular
potency [29].
That so little is known about vulnerability of essential proteins to
incomplete depletion is in part due to the difficulties we and others
have experienced in constructing phenotypically well-regulated
conditional Mtb knockdown mutants. Here, we overcame a key
technical hurdle associated with evaluating a potential drug target
in vitro and in mice: the leakiness of transcriptional regulatory
systems, which can often prevent efficient silencing of proteins
required only in small amounts, for which we developed a novel
translational regulatory strategy. This may provide a generally
applicable approach that will enable vulnerability to be added as a
parameter of target validation. Such information should help to
further focus target-based drug discovery efforts on pathways and
enzymes that are essential under a variety of conditions and are
susceptible to incomplete inhibition.
Material and Methods
Ethics statement
All procedures including animal studies were conducted
following the National Institutes of Health guidelines for housing
and care of laboratory animals and performed in accordance with
institutional regulations after protocol review and approval by the
Institutional Animal Care and Use Committee of Weill Cornell
Medical College (protocol # 0802-713A, TetR-controlled gene
silencing in mycobacteria during mouse infections).
Strains, media and culture conditions
Mtb H37Rv was obtained from Dr. Robert North (Trudeau
Institute) and grown in Sauton’s liquid medium containing 0.02%
tyloxapol, or in Middlebrook 7H9 liquid medium (Difco)
containing 0.2% glycerol, 0.5% BSA, 0.2% dextrose, 0.085%
NaCl, and 0.05% Tween 80, or on Middlebrook 7H11 agar plates
containing 10% OADC supplement (Becton Dickinson) and 0.5%
glycerol. When required, hygromycin B was used at a concentra-
tion of 50 or 100 mg/ml and kanamycin at a concentration of
15 mg/ml. Preparation of competent cells, electroporations, and
preparation of genomic DNA were performed as described [19].
Where indicated, 7-keto-8-aminopelargonic acid (KAPA; Toronto
Research Chemicals), DTB (Sigma), and biotin (Sigma) were
added at a concentration of 1 mM.
Mutant construction and southern blotting
BioA was deleted by homologous recombination following
transduction with a derivative of the temperature sensitive
mycobacteriophage phAE87 [30]. To generate this phage the
39-portion of the rv1567c was amplified by PCR, digested with
BglII and NcoI and cloned into likewise digested pJSC284 (gift of J.
S. Cox) resulting in pJSC284-Rv1567c. We then amplified the bioA
promoter region and the 59-portion of bioF using primers that
allowed us to fuse these two amplicons in a third PCR. The
resulting PCR product (in which the bioA promoter region was
located upstream of the 59-portion of bioF) was cloned downstream
of the hygromycin resistance cassette of pJSC284 using AflII and
AgeI. This resulted in pJSC284-Rv1567c-bioF, which contained
the complete bioA knockout cassette. The integrity of pJSC284-
Rv1567c-bioF was confirmed by restrictions and DNA sequenc-
ing. pJSC284-Rv1567c-bioF was used to construct a bioA knockout
Figure 7. Quantitative BioA immunoblotting of bioA TetON-1 and bioA TetON-5. Immunoblots were performed as described in the main
text and in the material and methods.
doi:10.1371/journal.ppat.1002264.g007
Table 1. Relative BioA protein levels and activities.
BioA protein* BioA activity*
Plus atc Minus atc Plus atc Minus atc
Mtb DbioA ,1% ,1% ,1% ,1%
Mtb bioA TetON-1 1,160% 7% 1,526% 6 483% 4.3% 6 2.3%
Mtb bioA TetON-2 230% ,1% 320% 6 22% ,1%
Mtb bioA TetON-3 184% ,1% 403% 6 64% ,1%
Mtb bioA TetON-4 14% ,1% 36% 6 4% ,1%
Mtb bioA TetON-5 9% ,1% 25% 6 14% ,1%
*BioA protein levels and BioA activities are expressed relative to wt Mtb, which
was defined to express 100% BioA protein/activity. BioA activity error estimates
represent standard deviations of up to four measurements.
doi:10.1371/journal.ppat.1002264.t001
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Mtb were selected on 7H11 agar and obtained after 3 weeks of
incubation at 37uC. Mutants were analyzed by PCR and Southern
blotting. For Southern blotting genomic DNA was digested with
DraIII and analyzed with a probe specific for bioF. Hybridization
and detection were carried out with an ECL chemoluminescent
detection system (GE Healthcare) as instructed by the manufac-
turer. BioA-TetON mutants were obtained by transformation of
DbioA with expression plasmids that integrate into the attachment
site of the mycobacteriophage L5, contain bioA downstream of
Pmyc1tetO [19] and also contained tetR#2 [20]. These plasmids
were constructed using gateway recombination as described [32].
Immunoblots
Cell lysates were prepared by bead-beating cell pellets in lysis
buffer (25 mM Tris HCl [pH 7.6], 1 mM EDTA, and 1 mM
PMSF) and sterilized by passage through a 0.22 mm Spin-X filter
(Costar). For the detection of biotinylated proteins, 15 mg cell
lysates were subjected to SDS-PAGE, followed by transfer to a
nitrocellulose membrane. Biotin-specific mouse serum (Sigma) and
DlaT-specific rabbit serum [33] were used at 1:1,000 dilutions in
blocking buffer. For the detection of BioA proteins, cell lysates
were subjected to SDS-PAGE and blots were probed with BioA-
specific rabbit serum (1:1,000) generated against purified BioA
protein. Goat anti-mouse and goat anti-rabbit (LI-COR Biosci-
ences) were diluted 1:10,000 in Odyssey blocking buffer. Blots
were developed using the Odyssey Infrared Imaging System (LI-
COR Biosciences).
BioA activity assay
Bacteria were grown in at least 500 ml Sauton’s media
containing 1 mM biotin in the presence or absence of atc. Once
the culture reached an OD580 of , 1.0, bacteria were harvested by
centrifugation, washed, and resuspended in lysis buffer (100 mM
bicine pH 8.6, 50 mM NaHCO3, 1 mM MgCl2, 0.0025% igepal
CA-630, and protease inhibitor cocktail tablet [Roche]). Cell free
lysates were prepared by beating the solution with 0.1 mm
Zirconia/Silica beads (BioSpec Products, Inc) three times at
6000 rpm for 50 sec at 4uC, followed by 10 min centrifugation at
13000 rpm, 4uC and sterilized by passage through a 0.22 mm
Spin-X filter (Costar). BioA activity in the lysates was quantified
using a coupled assay employing BioD to generate DTB, which
was subsequently detected in a fluorescence displacement assay.
BioA and BioD were expressed and purified as described (Wilson,
D. J. et al., submitted) Biotin and biotinylated proteins were
removed from cell free lysates by the addition of 100 mL
streptavidin agarose resin (Thermo Scientific 20349) that had
been pre-washed with PBS to remove storage buffer.
Samples were incubated for 30 min at 4uC, spun at 1000 6g
for 1 min, and the biotin free supernatant was retrieved. Reactions
were then prepared in duplicate in 500 mL total volume and
contained 200 mL biotin-free Mtb lysate (1–20 mg protein/mL),
12.5 mM KAPA, 5 mM SAM, 1 mM TCEP, 5 mM ATP,
200 mM PLP in reaction buffer (100 mM bicine pH 8.6, 50 mM
NaHCO3, 1 mM MgCl2, 0.0025% igepal CA-630). Reactions
were initiated by the addition of 320 nM BioD and incubated at
37uC for 16 hours. Control reactions were made by omitting BioD
or freezing control reactions at 280uC. Both controls yielded
identical results. DTB formed was removed from reactions by the
addition of 30 mL of streptavidin agarose resin followed by
incubation at 4uC for 30 min. Resin was pelleted at 1000 6g for
1 min and the resin was washed with 300 mL reaction buffer plus
10 mM MgCl2. DTB was removed from the resin by incubating
the beads with 47 mL of water for 5 min at 110uC. The free DTB
was detected by transferring 45 mL of the reaction mixture into a
black 384 well plate (corning 3575) and adding N
1-[3-[2-(2-{3-
[(Fluorescein-5-yl)carbonyl]aminopropoxy}ethoxy)ethoxy]propyl}
dethiobiotinamide (Fl-DTB) [34] and streptavidin (Sigma S4762)
providing a final concentration of 20 nM and 185 nM, respec-
tively in a total of 50 mL. Plates were incubated for 10 min and
read on a molecular devices M5e multi mode plate reader using
excitation 485, emission 530, and cutoff 530 nm. To quantitate
the amount of DTB produced a standard curve was produced by
adding known quantities of DTB to reactions containing lysate
from the DbioA mutant (see Figure S6 for a representative standard






where F is the fluorescence intensity at DTB concentration [S],
Fmax and Fmin are the maximum and minimum fluorescence
signals respectively and IC50 is the concentration of DTB that
produces 50% Fmax. Fluorescence was then converted back into





Experiments to determine that the amount of DTB produced was
directly proportional to the concentration of BioA were performed
by adding 0, 0.5, 1,0, and 2.0 nM recombinant BioA to the
standard reaction above using lysate from the DbioA mutant
(2 mg/mL). The amount of DTB produced per concentration of
BioA was fit with linear regression analysis using Prism (Figure S5).
Mouse infections
8–10 week old C57BL/6 mice were purchased from Jackson
Laboratory and infected with the indicated Mtb strains by aerosol
as described [35]. When indicated, mice received doxycycline
containing mouse chow (2,000 ppm; Research Diets). Serial
dilutions of organ homogenates from four mice per data point
were plated onto 7H11 agar plates to quantify CFUs. When
histopathology analyses were performed, the upper left lobes of
infected lungs were fixed in 10% buffered formalin, sectioned and
stained with hematoxylin and eosin (Laboratory of Comparative
Pathology at Memorial Sloan-Kettering Cancer Center).
Supporting Information
Figure S1 In vitro growth of Mtb bioA TetON mutants.
Growth of wt and bioA TetON-1/2/3/4/5 in biotin-free Sauton’s
medium with and without atc and in biotin-containing Sauton’s
medium. Data are from individual cultures and representative of
at least two independent experiments.
(TIF)
Figure S2 Atc dose-responsive growth of bioA TetON-5.
Growth of bioA TetON-5 in biotin-free Sauton’s with the indicated
atc concentrations was analyzed in 96-well microtiter plates. The
culture volume per well was 100 mL and growth was measured
after incubation at 37uC for 20 days.
(TIF)
Figure S3 Histopathology of mouse lungs infected with
Mtb bioA TetON-5. Each panel shows sections of entire lobes
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lung at larger magnification on the left.
(TIF)
Figure S4 Schematic diagram of the BioA activity assay.
DTB is generated from KAPA using BioA (either recombinant
protein or Mtb protein extract) and recombinant BioD in a reaction
containing saturating concentrations of all substrates (SAM, ATP,
HCO3) and required cofactors (PLP, Mg
2+). DTB is subsequently
detected by displacement of a fluorescently labeled DTB analog (Fl-
DTB, shown as either black/quenched or green/fluorescent) from
streptavidin (grey oval) resulting in an increase in the fluorescent
signal. Assay details are described in the materials and methods.
(TIF)
Figure S5 Standard curve of recombinant BioA activity.
Each reaction contained 200 mLT BDbioA lysate (2 mg/mL), 0.5,
1, or 2 nM BioA, 12.5 mM KAPA, 5 mM SAM, 1 mM TCEP,
5 mM ATP, 200 mM PLP and 320 nM BioD in reaction buffer
(100 mM Bicine pH 8.6, 50 mM NaHCO3, 1 mM MgCl2,
0.0025% igepal CA-630) and was processed as described in the
materials and methods.
(TIF)
Figure S6 Standard curve of displacement of Fl-DTB by
DTB. Each reaction contained 200 mLT BDbioA lysate (4 mg/
mL), 12.5 mM KAPA, 5 mM SAM, 1 mM TCEP, 5 mM ATP,
200 mM PLP and 0–500 nM dethiobiotin in reaction buffer
(100 mM Bicine pH 8.6, 50 mM NaHCO3, 1 mM MgCl2,
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